{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:22:20Z","timestamp":1790259740563,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1186\/1756-9966-29-166","type":"journal-article","created":{"date-parts":[[2011,1,5]],"date-time":"2011-01-05T14:27:00Z","timestamp":1294237620000},"source":"Crossref","is-referenced-by-count":9,"title":["Incidence of high chromogranin A serum levels in patients with non metastatic prostate adenocarcinoma"],"prefix":"10.1186","volume":"29","author":[{"given":"Marialuisa","family":"Appetecchia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurela","family":"Me\u00e7ule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Pasimeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta V","family":"Iannucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"De Carli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Baldelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnese","family":"Barnabei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Cigliana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Sperduti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Gallucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,12,17]]},"reference":[{"key":"413_CR1","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0302-2838(03)00257-4","volume":"44","author":"T Hvamstad","year":"2003","unstructured":"Hvamstad T, Jordal A, Hekmat N, et al: Neuroendocrine serum tumour markers in hormone-resistant prostate cancer. Eur Urol. 2003, 44: 215-21. 10.1016\/S0302-2838(03)00257-4.","journal-title":"Eur Urol"},{"key":"413_CR2","first-page":"855","volume-title":"Genitourinary oncology","author":"DC Smith","year":"2000","unstructured":"Smith DC, Dawson NA, Trump DL: Secondary hormonal manipulation. Genitourinary oncology. 2000, Philadelphia Lippincott Williams & Wilkins, 855-76. 2","edition":"2"},{"key":"413_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/(SICI)1097-0045(1998)8+<18::AID-PROS4>3.0.CO;2-C","volume":"8","author":"H Bonkhoff","year":"1998","unstructured":"Bonkhoff H: Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status. Prostate. 1998, 8: 18-22,. 10.1002\/(SICI)1097-0045(1998)8+<18::AID-PROS4>3.0.CO;2-C.","journal-title":"Prostate"},{"key":"413_CR4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1023\/A:1012407027175","volume":"12","author":"J Hansson","year":"2001","unstructured":"Hansson J, Abrahamsson PA: Neuroendocrine pathogenesis in adenocarcinoma of the prostate. Ann Oncol. 2001, 12: 145-S152. 10.1023\/A:1012407027175.","journal-title":"Ann Oncol"},{"key":"413_CR5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/(SICI)1097-0045(20000301)42:4<295::AID-PROS7>3.0.CO;2-B","volume":"42","author":"B Sun","year":"2000","unstructured":"Sun B, Halmos G, Schally AV, et al: Presence of receptors for bombesin\/gastrin releasing peptide and mRNA for three receptors subtypes in human prostate cancer. Prostate. 2000, 42: 295-303. 10.1002\/(SICI)1097-0045(20000301)42:4<295::AID-PROS7>3.0.CO;2-B.","journal-title":"Prostate"},{"key":"413_CR6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1677\/erc.1.00876","volume":"12","author":"A Berruti","year":"2005","unstructured":"Berruti A, Mosca A, Tucci M, et al: Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone refractory disease. Endocr Relat Cancer. 2005, 12: 109-17. 10.1677\/erc.1.00876.","journal-title":"Endocr Relat Cancer"},{"key":"413_CR7","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0022-5347(17)37793-5","volume":"146","author":"D Kadmon","year":"1991","unstructured":"Kadmon D, Thomson TC, Lynch GR, et al: Elevated plasma chromogranin A concentrations in prostatic carcinoma. J Urol. 1991, 146: 358-361.","journal-title":"J Urol"},{"key":"413_CR8","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/S0022-5347(05)67714-2","volume":"163","author":"R Ischia","year":"2000","unstructured":"Ischia R, Hobisch A, Bauer R, et al: Elevated levels of serum secretoneurin in patients with therapy resistant carcinoma of prostate. J Urol. 2000, 163: 1161-1165. 10.1016\/S0022-5347(05)67714-2.","journal-title":"J Urol"},{"key":"413_CR9","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1046\/j.1464-4096.2001.001223.x","volume":"88","author":"M Ferrero-Pous","year":"2001","unstructured":"Ferrero-Pous M, Hersant AM, Pecking A, et al: Serum chromogranin A in advanced prostate cancer. Br J Urol Int. 2001, 88: 790-6.","journal-title":"Br J Urol Int"},{"key":"413_CR10","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/pros.10347","volume":"58","author":"A Sciarpa","year":"2004","unstructured":"Sciarpa A, Voria G, Monti S, et al: Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum Chromogranin A. Prostate. 2004, 58: 421-428. 10.1002\/pros.10347.","journal-title":"Prostate"},{"key":"413_CR11","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0090-4295(00)00838-4","volume":"56","author":"G Ahlegren","year":"2000","unstructured":"Ahlegren G, Pedersen K, Lundberg S, et al: Neuroendocrine differentiation is not prognostic of failure after radical prostatectomy but correlates with tumor volume. Urology. 2000, 56: 1011-1015. 10.1016\/S0090-4295(00)00838-4.","journal-title":"Urology"},{"key":"413_CR12","unstructured":"TNM classification of malignant tumors. Edited by: Sobin LH, Wittekind Ch. 2002, --- Either ISSN or Journal title must be supplied.. 6"},{"key":"413_CR13","first-page":"15","volume-title":"NCI Monogr","author":"DF Gleason","year":"1988","unstructured":"Gleason DF: Histologic grade, clinical stage, and patient age in prostate cancer. NCI Monogr. 1988, 15-8."},{"key":"413_CR14","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1046\/j.1464-4096.2001.001223.x","volume":"88","author":"M Ferrero-Po\u00fcs","year":"2001","unstructured":"Ferrero-Po\u00fcs M, Hersant AM, Pecking A, et al: Serum chromogranin-A in advanced prostate cancer. BJU Int. 2001, 88: 790-6.","journal-title":"BJU Int"},{"key":"413_CR15","first-page":"1373","volume":"52","author":"A Sciarra","year":"2007","unstructured":"Sciarra A: Neuroendocrine differentiation in prostate adenocarcinoma. Eur Urol. 2007, 52: 1373-","journal-title":"Eur Urol"},{"key":"413_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/(SICI)1097-0045(19970101)30:1<1::AID-PROS1>3.0.CO;2-T","volume":"30","author":"A Angelsen","year":"1997","unstructured":"Angelsen A, Syversen U, Haugen OA, et al: Neuroendocrine differentiation in carcinomas of prostate: do neuroendocrine serum markers reflect immunohistochemical findings?. Prostate. 1997, 30: 1-6. 10.1002\/(SICI)1097-0045(19970101)30:1<1::AID-PROS1>3.0.CO;2-T.","journal-title":"Prostate"},{"key":"413_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/pros.1076","volume":"48","author":"N Xing","year":"2001","unstructured":"Xing N, Qian J, Bostwick D, et al: Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin. Prostate. 2001, 48: 7-15. 10.1002\/pros.1076.","journal-title":"Prostate"},{"key":"413_CR18","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/pros.20493","volume":"67","author":"S Shimizu","year":"2007","unstructured":"Shimizu S, Kumagai J, Eishi Y, et al: Frequency and number of neuroendocrine tumor cells in prostate cancer: no difference between radical prostatectomy specimens from patients with and without neoadjuvant hormonal therapy. Prostate. 2007, 67: 645-52. 10.1002\/pros.20493.","journal-title":"Prostate"},{"key":"413_CR19","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/pros.10133","volume":"53","author":"T Fixemer","year":"2002","unstructured":"Fixemer T, Remberger K, Bonkhoff H: Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma. Prostate. 2002, 53: 118-23. 10.1002\/pros.10133.","journal-title":"Prostate"},{"key":"413_CR20","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","volume":"14","author":"IF Tannock","year":"1996","unstructured":"Tannock IF, Osoba D, Stockler MR, et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996, 14: 1756-64.","journal-title":"J Clin Oncol"},{"key":"413_CR21","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/S0022-5347(01)66261-X","volume":"155","author":"O Cussenot","year":"1996","unstructured":"Cussenot O, Villette JM, Valeri A, et al: Plasma neuroendocrine markers in patients with benign prostatic hypertrophy and prostate carcinoma. J Urol. 1996, 155: 1340-1343. 10.1016\/S0022-5347(01)66261-X.","journal-title":"J Urol"},{"key":"413_CR22","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/(SICI)1097-0045(20000301)42:4<274::AID-PROS4>3.0.CO;2-R","volume":"42","author":"G Ahlegren","year":"2000","unstructured":"Ahlegren G, Pedersen K, Lundberg S, et al: Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment. Prostate. 2000, 42: 274-279. 10.1002\/(SICI)1097-0045(20000301)42:4<274::AID-PROS4>3.0.CO;2-R.","journal-title":"Prostate"},{"key":"413_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0302-2838(03)00257-4","volume":"44","author":"T Hvamstad","year":"2003","unstructured":"Hvamstad T, Jordal A, Hekmat N, et al: Neuroendocrine serum tumour markers in hormone-resistant prostate cancer. Eur Urol. 2003, 44: 215-221. 10.1016\/S0302-2838(03)00257-4.","journal-title":"Eur Urol"},{"key":"413_CR24","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.dld.2003.11.021","volume":"36","author":"A Mosca","year":"2004","unstructured":"Mosca A, Dogliotti L, Berruti A, et al: Somatostatin receptors: from basic science to clinical approach. Unlabeled somatostatin analogues-1: prostate cancer. Dig Liver Dis. 2004, 36: 60-S67. 10.1016\/j.dld.2003.11.021.","journal-title":"Dig Liver Dis"},{"key":"413_CR25","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/S0022-5347(01)69075-X","volume":"167","author":"S Isshiki","year":"2002","unstructured":"Isshiki S, Akakura K, Komiya A, et al: Chromogranin A concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol. 2002, 167: 512-515. 10.1016\/S0022-5347(01)69075-X.","journal-title":"J Urol"},{"key":"413_CR26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.archger.2005.09.008","volume":"43","author":"S Ranno","year":"2006","unstructured":"Ranno S, Motta M, Rampello E, et al: The chromogranin-A (CgA) in prostate cancer. Arch Gerontol Geriatr. 2006, 43: 117-26. 10.1016\/j.archger.2005.09.008.","journal-title":"Arch Gerontol Geriatr"},{"key":"413_CR27","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0022-5347(01)65203-0","volume":"157","author":"N Kimura","year":"1997","unstructured":"Kimura N, Hoshi S, Takahashi M, et al: Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors. J Urol. 1997, 157: 565-7. 10.1016\/S0022-5347(01)65203-0.","journal-title":"J Urol"},{"key":"413_CR28","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.eururo.2003.11.032","volume":"45","author":"D Hirano","year":"2004","unstructured":"Hirano D, Okada Y, Minei S, et al: Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol. 2004, 45: 586-592. 10.1016\/j.eururo.2003.11.032.","journal-title":"Eur Urol"},{"key":"413_CR29","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/172460080602100406","volume":"21","author":"F Grimaldi","year":"2006","unstructured":"Grimaldi F, Valotto C, Barbina G, et al: The possible role of chromogranin A as a prognostic factor in organ-confined prostate cancer. Int J Biol Markers. 2006, 21: 229-34.","journal-title":"Int J Biol Markers"},{"key":"413_CR30","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1002\/1097-0142(19930615)71:12<3952::AID-CNCR2820711226>3.0.CO;2-X","volume":"71","author":"AG Aprikian","year":"1993","unstructured":"Aprikian AG, Cordon-Cardo C, Fair W, et al: Characterization of neuroendocrine differentiation in human benign prostate and prostate adenocarcinoma. Cancer. 1993, 71: 3952-65. 10.1002\/1097-0142(19930615)71:12<3952::AID-CNCR2820711226>3.0.CO;2-X.","journal-title":"Cancer"},{"key":"413_CR31","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/(SICI)1097-0045(19980201)34:2<113::AID-PROS5>3.0.CO;2-L","volume":"34","author":"G Pruneti","year":"1998","unstructured":"Pruneti G, Galli S, Rossi RS, et al: Chromogranin A and B secretogranin II in prostatic adenocarcinomas: neuroendocrine expression in patients untreated and treated with androgen deprivation therapy. Prostate. 1998, 34: 113-20. 10.1002\/(SICI)1097-0045(19980201)34:2<113::AID-PROS5>3.0.CO;2-L.","journal-title":"Prostate"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-9966-29-166.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1756-9966-29-166\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-9966-29-166.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T03:20:59Z","timestamp":1548213659000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/1756-9966-29-166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["413"],"URL":"https:\/\/doi.org\/10.1186\/1756-9966-29-166","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12]]},"article-number":"166"}}